NCT06152042
Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus
Phase 2 Randomized, Double-blind Trial of BMF-219 Compared to Placebo in Participants With Type 1 Diabetes Mellitus
Biomea Fusion Inc.·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Type 1 Diabetes Mellitus
- Drug/Device/Intervention
- BMF-219
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Biomea Fusion Inc.
Timeline & enrollment
- Phase
- Phase 2
- Start date
- Nov 30, 2023
- End date
- Aug 31, 2025
- Enrollment
- 150 participants
Primary outcome
To assess the effect on endogenous insulin secretion
Summary
Phase 2 Trial of BMF-219 in Participants with Type 1 Diabetes Mellitus.
ICD-10 classifications
Type 1 diabetes mellitusType 1 diabetes mellitus with unspecified complicationsType 1 diabetes mellitus with other specified complicationsType 1 diabetes mellitus without complicationsType 1 diabetes mellitus with multiple complications
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06152042
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06152042 through Pure Global AI's free database. This Phase 2 trial is sponsored by Biomea Fusion Inc. and is currently Not yet recruiting. The study focuses on Type 1 Diabetes Mellitus. Target enrollment is 150 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.